[go: up one dir, main page]

WO1998000535A3 - Procede pour inhiber l'infection par le vih-1, dosages de medicaments et procedes de diagnostic et pronostic de la susceptibilite d'infection par le vih - Google Patents

Procede pour inhiber l'infection par le vih-1, dosages de medicaments et procedes de diagnostic et pronostic de la susceptibilite d'infection par le vih Download PDF

Info

Publication number
WO1998000535A3
WO1998000535A3 PCT/US1997/012701 US9712701W WO9800535A3 WO 1998000535 A3 WO1998000535 A3 WO 1998000535A3 US 9712701 W US9712701 W US 9712701W WO 9800535 A3 WO9800535 A3 WO 9800535A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
binding
hiv
prognosis
susceptibility
Prior art date
Application number
PCT/US1997/012701
Other languages
English (en)
Other versions
WO1998000535A2 (fr
Inventor
Joseph G Sodroski
Walter Newman
Hye-Ryun Choe
Lijun Wu
Norma Gerard
Craig Gerard
Original Assignee
Danafarber Cancer Inst
Joseph G Sodroski
Walter Newman
Hye-Ryun Choe
Lijun Wu
Norma Gerard
Craig Gerard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danafarber Cancer Inst, Joseph G Sodroski, Walter Newman, Hye-Ryun Choe, Lijun Wu, Norma Gerard, Craig Gerard filed Critical Danafarber Cancer Inst
Priority to AU39607/97A priority Critical patent/AU3960797A/en
Publication of WO1998000535A2 publication Critical patent/WO1998000535A2/fr
Publication of WO1998000535A3 publication Critical patent/WO1998000535A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux récepteurs de la chémokine β qui facilitent l'entrée cellulaire de souches de HIV-1 macrophages tropiques primaires. CCR5 et CCR3 facilitent l'entrée de souches de HIV-1 macrophages tropiques. L'invention a aussi pour objet un site de liaison de conformation gp 120 qui est formé par la liaison de gp 120 et CD4 qui permet la liaison du complexe aux récepteurs de chémokine. L'invention traite également d'essais de fixation qui permettent de détecter rapidement les molécules affectant la liaison de gp 120 et de la chémokine ainsi que des cibles spécifiques pour affecter la liaison.
PCT/US1997/012701 1996-06-28 1997-06-27 Procede pour inhiber l'infection par le vih-1, dosages de medicaments et procedes de diagnostic et pronostic de la susceptibilite d'infection par le vih WO1998000535A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39607/97A AU3960797A (en) 1996-06-28 1997-06-27 Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2083096P 1996-06-28 1996-06-28
US60/020,830 1996-06-28
US2793196P 1996-10-09 1996-10-09
US60/027,931 1996-10-09
US3672997P 1997-01-24 1997-01-24
US60/036,729 1997-01-24

Publications (2)

Publication Number Publication Date
WO1998000535A2 WO1998000535A2 (fr) 1998-01-08
WO1998000535A3 true WO1998000535A3 (fr) 1998-06-18

Family

ID=27361523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012701 WO1998000535A2 (fr) 1996-06-28 1997-06-27 Procede pour inhiber l'infection par le vih-1, dosages de medicaments et procedes de diagnostic et pronostic de la susceptibilite d'infection par le vih

Country Status (2)

Country Link
AU (1) AU3960797A (fr)
WO (1) WO1998000535A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6461809B1 (en) 1996-10-15 2002-10-08 Bio-Tech Imaging, Inc Methods of improving infectivity of cells for viruses
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
WO1998034945A1 (fr) * 1997-02-06 1998-08-13 Epoch Pharmaceuticals, Inc. Modification ciblee du gene ccr-5
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU9495098A (en) * 1997-09-19 1999-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for use of interleukin 4 (il-4) to treat human immunodeficiency virus infection
EP1088108A4 (fr) * 1998-06-23 2002-04-17 Uab Research Foundation Analyse a base de cellules pour determiner l'infectivite et la sensibilite du virus vih
US6797462B1 (en) 1998-06-23 2004-09-28 Uab Research Foundation Cell-based assay for immunodeficiency virus infectivity and sensitivity
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
EP1118858A3 (fr) * 2000-01-12 2003-07-09 Pfizer Limited Méthode d'essai
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2005105841A2 (fr) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Récepteur humain (ccr5) hdgnr10 de chimiokine de la protéine g

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026305A1 (fr) * 1993-05-07 1994-11-24 Akzo Nobel N.V. Complexes immunogenes de v.i.h.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026305A1 (fr) * 1993-05-07 1994-11-24 Akzo Nobel N.V. Complexes immunogenes de v.i.h.

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
H. CHOE ET AL.: "The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.", CELL, vol. 85, no. 7, 28 June 1996 (1996-06-28), CAMBRIDGE, MA, USA, pages 1135 - 1148, XP002061250 *
H. DENG ET AL.: "Identification of a major co-receptor for primary isolates of HIV-1.", NATURE, vol. 381, no. 6584, 20 June 1996 (1996-06-20), LONDON, GB, pages 661 - 666, XP002061247 *
J. MOORE ET AL.: "Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein or human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.", JOURNAL OF VIROLOGY, vol. 67, no. 2, February 1993 (1993-02-01), BALTIMORE, MD, USA, pages 863 - 875, XP002061248 *
L. WU ET AL.: "CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 9, 5 May 1997 (1997-05-05), NEW YORK, NY, USA, pages 1681 - 1691, XP002061252 *
L. WU ET AL.: "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.", NATURE, vol. 384, no. 6605, 14 November 1996 (1996-11-14), LONDON, GB, pages 179 - 183, XP002061251 *
M. THALI ET AL.: "Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.", JOURNAL OF VIROLOGY, vol. 67, no. 7, July 1993 (1993-07-01), BALTIMORE, MD, USA, pages 3978 - 3988, XP002061249 *
S. WAIN-HOBSON: "One on one meets two.", NATURE, vol. 384, no. 6605, 14 November 1996 (1996-11-14), LONDON, GB, pages 117 - 118, XP002061253 *
T. DRAGIC ET AL.: "HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.", NATURE, vol. 381, no. 6584, 20 June 1996 (1996-06-20), LONDON, GB, pages 667 - 673, XP002061246 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Also Published As

Publication number Publication date
WO1998000535A2 (fr) 1998-01-08
AU3960797A (en) 1998-01-21

Similar Documents

Publication Publication Date Title
WO1998000535A3 (fr) Procede pour inhiber l'infection par le vih-1, dosages de medicaments et procedes de diagnostic et pronostic de la susceptibilite d'infection par le vih
Elison et al. Effect of deuteration of N—CH3 group on potency and enzymatic N-demethylation of morphine
EP0891982A3 (fr) Peptides de VIH
WO1998018826A3 (fr) Anticorps anti-ccr5 et procedes d'utilisation correspondants
ATE405679T1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
DE69029036D1 (de) Bispezifische reagenzien für die aids-therapie
CA2224003A1 (fr) Methode de determination de transfert d'energie resonante par fluorescence servant a identifier la cellule de glycoproteine d'enveloppe de hiv-1
AU5059685A (en) Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
EP0547056B1 (fr) Procede de determination de l'activite de polymerases
EP0673948A1 (fr) Peptides dérivés d'un rétrovirus du groupe SIV et leur utilisation
EP0372466A3 (fr) 2-Amino-4- ou 5-méthoxycyclohexyl amides utilisables comme analgésiques
Smith et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy
OA08652A (fr) Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus HIV et procédés de production de ces anticorps et de diagnostic de la présence de ce virus.
EP0253319A3 (fr) Procédé de préparation de dérivés spiro de la pyrrolidine-2,5-dione
GB9318612D0 (en) An assay
JP2004536777A (ja) レトロウィルスの細胞進入促進剤を用いる方法
DE60015312T2 (de) Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon
WO1993001820A3 (fr) Inhibition de l'infection hiv a mediation par la proteine non-cd4
Mahieux et al. Cell cycle regulation of human interleukin-8 gene expression by the human immunodeficiency virus type 1 Tat protein
Furchner et al. The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A* 01 class I molecule
DE60208787T2 (de) Verfahren zum messen der polymerisierung von dna und anwendungen des verfahrens
MYERS Assimilating HIV sequences
Levy et al. Absence of antibodies to the human immunodeficiency virus in sera from Africa prior to 1975.
Tamura et al. STUDIES ON 3. 5-DIOXOPIPERIDINES: lr2 NOVEL AND FACILE SYNTHETIC ROUTES TO 3-AMINO-5-HYDROXYPYRIDINE DERIVATIVES
US5283344A (en) Coupling method using selective amination of maleimide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09217047

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98504529

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase